| Literature DB >> 34993341 |
Michelle Eder1, Ilya Ivlev1, Jennifer S Lin1.
Abstract
Aims. This methods project was conducted to support the US Preventive Services Task Force's (USPSTF) consideration of how information pertinent to shared decision making (SDM) can be best communicated in its recommendations. Methods. The project included a literature scan to identify SDM frameworks, audit of six USPSTF recommendations to judge the completeness of SDM communication, input from eight SDM experts on the most helpful SDM guidance to provide in USPSTF recommendations, and review of USPSTF recommendations and evidence reports to establish criteria for identifying topics that would most benefit from additional communication resources. Results. We identified eight SDM frameworks and selected one to guide the audit of USPSTF recommendations. All six recommendations include SDM elements related to the patient's role in decision making, preventive service being considered, pros and cons of options, uncertainties about benefits and harms, and importance of patient preferences. Two SDM elements are not routinely communicated in the recommendations-identification of not screening or initiating preventive medication as an alternative and the importance of patient understanding of options. Experts offered suggestions for essential SDM elements to address, such as assessing decisional conflict to measure patient uncertainty in choosing an option and highlighting uncertainty in estimates of benefit and harm, credibility of the evidence base, precision of estimates, and applicability to the individual patient. We developed six criteria for selection of USPSTF recommendations to supplement with a communication resource. Conclusions. The findings of this project can assist the USPSTF and other clinical guideline developers in incorporating SDM information in recommendations and determining which topics would most benefit from additional communication resources to support clinicians in engaging patients in SDM.Entities:
Keywords: clinical practice guidelines; communication resources; primary care; shared decision making
Year: 2021 PMID: 34993341 PMCID: PMC8725016 DOI: 10.1177/23814683211067522
Source DB: PubMed Journal: MDM Policy Pract ISSN: 2381-4683
Shared Decision Making (SDM) Elements in SDM Frameworks
| Author, Year | SDM Step, Element, or Competency | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Define Decision | Patient’s Role | Options | Pros and Cons of Options | Uncertainty/Equipoise | Check Understanding | Patient Values and Preferences | Make/Facilitate Decision | Follow-up | Other | |
| Towle & Godolphin, 1999
|
| √ | √ | √ | √ | √ | Develop partnership with patient; evaluate evidence in relation to patient; present evidence | |||
| Braddock et al., 1999
| √ | √ | √ | √ | √ | √ | √ | |||
| Sheridan et al., 2004
| √ | √ | √ | √ | √ | √ | √ | Assess patient’s health needs (acute issues, eligibility for preventive services); deliver or prescribe service | ||
| Makoul & Clayman, 2006
| √ | √ | √ | √ | √ | √ | √ | Discuss patient ability/self-efficacy; consider doctor knowledge/recommendations | ||
| National Learning Consortium, 2013
| √ | √ | √ | √ | √ | √ | ||||
| Volk et al., 2014
| √ | √ | √ | √ | √ | √ | √ | √ | √ | |
| Stiggelbout et al., 2015
| √ | √ | √ | √ | √ | √ | √ | |||
| Rusiecki et al., 2018
| √ | √ | √ | √ | √ | √ | √ | √ | ||
Definitions for Shared Decision Making (SDM) Elements in Braddock Framework
| SDM Element | Definition for Audit |
|---|---|
| 1. Discussion of the | The patient’s involvement in the decision is mentioned (e.g., “patients [and clinicians] should consider . . .,”“patients [should work with their clinicians to] may choose . . .”) |
| 2. Discussion of the clinical issue or | The preventive service being considered is identified (e.g., “screening for prostate cancer”) |
| 3. Discussion of the | The options are identified (e.g., screen with test X or not) |
| 4. Discussion of the | Both the potential benefits and harms of options are described (e.g., reducing risk for cancer death versus false-positive result, unnecessary tests or procedures) |
| 5. Discussion of | Areas of uncertainty in the scientific evidence on the benefits and/or harms of the options (e.g., conflicting or limited data) are described [not USPSTF level of certainty regarding net benefit] |
| 6. Assessment of the | The importance of patient understanding of the options is mentioned |
| 7. Exploration of | The importance and role of patient values and/or preferences in the decision is mentioned |
Audit of Six USPSTF C Grade Recommendations
| Topic | SDM Element | ||||||
|---|---|---|---|---|---|---|---|
| Patient’s Role | Nature of Decision | Alternatives | Pros and Cons | Uncertainties | Patient Understanding | Patient Preference | |
| AAA (S) |
|
|
|
|
| ||
| Aspirin (PM) |
|
|
|
|
| ||
| Breast cancer (S) |
|
|
|
|
| ||
| Colorectal cancer (S) |
|
|
|
|
|
| |
| Prostate cancer (S) |
|
|
|
|
|
|
|
| Statins (PM) |
|
|
|
|
| ||
| Total | 6 | 6 | 2 | 6 | 6 | 1 | 6 |
AAA, abdominal aortic aneurysm; PM, preventive medication; S, screening; SDM, shared decision making; USPSTF, US Preventive Services Task Force.
Application of Selection Criteria: Two Examples
|
|
| In our assessment, this topic meets 5 of the selection criteria: |
| • New recommendation from USPSTF (criterion 1) |
| • Identification of persons at high risk of HIV acquisition can be challenging during the encounter (criterion 2) |
| • Decision to begin PrEP depends heavily on patient preferences and values because the degree of risk is hard to define (criterion 4) |
| • There are disparities in provision of PrEP (criterion 5) |
| • Suboptimal uptake—only 10% of eligible patients use PrEP[ |
|
|
| In our assessment, this topic meets 3 of the selection criteria: |
| • Assessing personal risk for breast cancer is challenging (criterion 2) |
| • Decision to begin risk-reducing medication depends heavily on patient preferences about breast cancer risk reduction and the potential benefits and harms of preventive medications (criterion 4) |
| • It is estimated that only 16% of women at increased risk for breast cancer use risk-reducing medications
|